alanine has been researched along with Dyskinesia, Drug-Induced in 8 studies
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.
alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.
Dyskinesia, Drug-Induced: Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Safinamide (Xadago(®)) is an oral α-aminoamide derivative developed by Newron for the treatment of Parkinson's disease (PD)." | 2.52 | Safinamide: first global approval. ( Deeks, ED, 2015) |
| "Safinamide (Xadago) is a novel dual-mechanism drug that has been approved in the European Union and United States as add-on treatment to levodopa in Parkinson's disease therapy." | 1.48 | Safinamide Modulates Striatal Glutamatergic Signaling in a Rat Model of Levodopa-Induced Dyskinesia. ( Brugnoli, A; Caccia, C; Gardoni, F; Keywood, C; Kulisevsky, J; Mellone, M; Melloni, E; Morari, M; Novello, S; Padoani, G; Pisanò, CA; Sosti, V; Vailati, S, 2018) |
| "Safinamide pre-treatment (3, 10, 20 and 30 mg/kg) dose-dependently reduced LID scores, in two acute and one semi-chronic experiment." | 1.39 | Safinamide reduces dyskinesias and prolongs L-DOPA antiparkinsonian effect in parkinsonian monkeys. ( Di Paolo, T; Grégoire, L; Jourdain, VA; Roach, A; Townsend, M, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gardoni, F | 1 |
| Morari, M | 1 |
| Kulisevsky, J | 1 |
| Brugnoli, A | 1 |
| Novello, S | 1 |
| Pisanò, CA | 1 |
| Caccia, C | 1 |
| Mellone, M | 1 |
| Melloni, E | 1 |
| Padoani, G | 1 |
| Sosti, V | 1 |
| Vailati, S | 1 |
| Keywood, C | 1 |
| Grégoire, L | 1 |
| Jourdain, VA | 1 |
| Townsend, M | 1 |
| Roach, A | 1 |
| Di Paolo, T | 1 |
| Borgohain, R | 1 |
| Szasz, J | 1 |
| Stanzione, P | 1 |
| Meshram, C | 1 |
| Bhatt, MH | 1 |
| Chirilineau, D | 1 |
| Stocchi, F | 1 |
| Lucini, V | 1 |
| Giuliani, R | 1 |
| Forrest, E | 1 |
| Rice, P | 1 |
| Anand, R | 1 |
| Deeks, ED | 1 |
| Pae, CU | 1 |
| Kim, TS | 1 |
| Patkar, AA | 1 |
| Kim, JJ | 1 |
| Lee, CU | 1 |
| Lee, SJ | 1 |
| Jun, TY | 1 |
| Lee, C | 1 |
| Paik, IH | 1 |
| Goff, DC | 1 |
| Tsai, G | 1 |
| Beal, MF | 1 |
| Coyle, JT | 1 |
| Silverdale, MA | 1 |
| Crossman, AR | 1 |
| Brotchie, JM | 1 |
2 reviews available for alanine and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
▼ Safinamide for Parkinson's disease.
Topics: Alanine; Benzylamines; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Monoam | 2018 |
Safinamide: first global approval.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Cognition Disorders; Drug Approval; Dyskinesia | 2015 |
1 trial available for alanine and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease.
Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Dose-Response Relationship, Drug; Double-Blind Me | 2014 |
5 other studies available for alanine and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
Safinamide Modulates Striatal Glutamatergic Signaling in a Rat Model of Levodopa-Induced Dyskinesia.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Corpus Striatum; Disease Models, Animal; Dopam | 2018 |
Safinamide reduces dyskinesias and prolongs L-DOPA antiparkinsonian effect in parkinsonian monkeys.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Dose-Response Relationship, Drug; Drug Synergi | 2013 |
Manganese superoxide dismutase (MnSOD: Ala-9Val) gene polymorphism may not be associated with schizophrenia and tardive dyskinesia.
Topics: Adult; Alanine; Alleles; Antipsychotic Agents; Chromosomes, Human, Pair 6; Dyskinesia, Drug-Induced; | 2007 |
Tardive dyskinesia and substrates of energy metabolism in CSF.
Topics: Adult; Alanine; Antipsychotic Agents; Aspartic Acid; Citric Acid Cycle; Dyskinesia, Drug-Induced; En | 1995 |
Striatal AMPA receptor binding is unaltered in the MPTP-lesioned macaque model of Parkinson's disease and dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alanine; Animals; Apomorphine; Autoradiography; Bindin | 2002 |